Ovid Therapeutics Inc.
04/20/2026 | Press release | Distributed by Public on 04/20/2026 06:17
Material Event (Form 8-K)
Item 8.01 Other Events.
On April 17, 2026, the Series A Warrants (the "Series A Warrants") issued by Ovid Therapeutics Inc. (the "Company") in connection with its October 2025 private placement expired. The aggregate number of common shares underlying the Series A Warrants was 38,481,325, and investors elected to exercise the warrants into 33,597,860 shares of the Company's common stock for $1.40 per share and 4,883,464 pre-funded warrants for $1.399 per share, resulting in gross proceeds to the Company of approximately $53.9 million.
Ovid Therapeutics Inc. published this content on April 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 20, 2026 at 12:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]